Jubilant IngreviaQ3 FY24

Jubilant Ingrevia Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹588.45P/E: 26.0Market Cap: ₹9.4K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

No

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2
  • Agrochemical segment expected to recover starting H1 FY25 with volume uptick by end Q4 FY24; potential 20-25% YoY growth anticipated.
  • Specialty Chemicals showing growth in non-agro segments like Diketene derivatives, microbial, CDMO, and Pharma, with capacity utilization targeted at 70%+ within 18 months.
  • Positive momentum in CDMO business, considered the fastest-growing segment in Specialty Chemicals, with prospects in pharma, agro, and semiconductor chemicals.
  • Capacity expansions underway: new agro intermediates and Diketene plants commissioning in Q4 FY24; Niacinamide facility by Q2 FY25.
  • Market share expected to increase due to competitor exit (Vertellus), potentially capturing 70-80% of displaced volumes in pyridine derivatives.
  • Overall company growth driven by successful CAPEX execution (Rs. 2,000 crore plan on track) and strategic partnerships.
  • Lean initiatives and cost controls aimed at improving profitability alongside volume growth.

See what Jubilant Ingrevia management said on margin guidance — free account, 30 seconds.

Fundraise plans

No
  • The company plans to complete the remaining Rs. 600 crore CAPEX out of the Rs. 2,000 crore plan by FY25 without expecting an increase in debt, assuming market recovery begins in Q1 FY25.
  • If the market recovery is delayed, the company may postpone additional CAPEX beyond the original plan by a few quarters to maintain current debt levels.
  • There is no indication of immediate new equity fundraising.
  • The company is maintaining financial discipline and plans to balance CAPEX with profitability, focusing on operating within existing debt limits.
  • Any new CAPEX items beyond the planned Rs. 2,000 crore will be considered cautiously and likely deferred if markets do not improve.
  • Net debt as of December 31, 2023 was Rs. 636 crore with a Net Debt to EBITDA ratio of 1.36x; efforts to reduce debt further through lean initiatives are ongoing.

See what Jubilant Ingrevia management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Remaining CAPEX of approx. Rs. 600 crore from the Rs. 2,000 crore plan will be deployed in FY25, mainly in Specialty Chemicals, Nutrition & Health segments, including agro chemical plants, food and cosmetic-grade niacinamide, value-added diketene derivatives, and new boiler and power plant at Bharuch.
  • Additional CAPEX plans are under internal review based on emerging opportunities and customer traction; any new CAPEX beyond the original Rs. 2,000 crore plan may be delayed by quarters if market recovery is slow.
  • Recent/completed CAPEX includes commissioning of an agro intermediates plant in Q3 FY24, with two more plants planned for Q4 FY24 (diketene derivative expansion and agro active cum intermediate).
  • A niacinamide plant (cosmetic and food-grade) is expected to start around June FY25.
  • The company is exploring strategic partnerships and new product segments such as semiconductor chemicals through its CDMO business.
  • Capital allocation aims at maintaining financial discipline without significant increase in debt assuming market recovery in Q1 FY25.

Track Jubilant Ingrevia — get its next earnings analysis in your feed

How does Jubilant Ingrevia rank vs peers in Chemicals & Petrochemicals?

Pro feature
ThisJubilant Ingrevia
Rev 2Mar 3

How does Jubilant Ingrevia rank in Chemicals & Petrochemicals?

Compare Jubilant Ingrevia against every Chemicals & Petrochemicals company (Q3 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

Others in Chemicals & Petrochemicals this season

  • Seya Industries (Q2 FY27)

    Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's

  • DCM Shriram Fine Chemicals (Q2 FY27)

    9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri

  • Dhariwalcorp (Q2 FY27)

    For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…

  • Agastya Energy (Q2 FY27)

    For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →